← Database
M&A

AMPLITUDE SURGICAL

Acquired by

ZYDUS

FRANCE Life Sciences EV [100m EUR - 500m EUR] 03/2025

Target

AMPLITUDE SURGICAL

Acquirer

ZYDUS

Context

Zydus entered into exclusive negotiations to acquire a controlling 85.6% stake (block trade) in Amplitude Surgical from PAI Partners, the management and minority shareholders. The offer price is EUR6.25 per share, representing an 80.6% premium over the pre-announcement share price. Following the block acquisition, Zydus will launch a mandatory simplified tender offer (OPAS) to acquire the remaining shares and intends to delist the company (squeeze-out) if the 90% threshold is reached.

AMPLITUDE SURGICAL, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.4x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Amplitude Surgical is a leading French MedTech company specializing in the design and manufacture of high-end orthopedic implants for lower-limb surgery (primarily Hip and Knee). Founded in 1997 in Valence, the group positions itself as a premium player, differentiating through a strong technological ecosystem that includes the AMPLIVISION computer-assisted navigation system and the i.M.A.G.E. single-use instrumentation platform. Following the strategic divestment of its foot and ankle division (Novastep) in 2023, the company refocused entirely on its core hip and knee segments, where it holds a strong #2 market position in France.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2024
LOGIN
LOGIN
LOGIN
2023
LOGIN
LOGIN
LOGIN

Other operations with AMPLITUDE SURGICAL

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.